Search results
Results from the WOW.Com Content Network
[81] [82] One of three children, Tharman is the son of Emeritus Professor K. Shanmugaratnam, [82] a medical scientist known as the "father of pathology in Singapore", who founded the Singapore Cancer Registry and led a number of international organisations related to cancer research and pathology. [83] [84] [85]
Cancer treatment centres in Singapore are generally located in both public and private hospitals. ... This page was last edited on 22 February 2022, at 21:12 (UTC).
The Cali Cancer Registry (Registro Poblacional de Cancer de Cali in Spanish) started in 1962 as a research program of the Department of Pathology of the University of Valle School of Medicine in Cali, Colombia. [17] Currently, Cali Cancer Registry is recognized by the International Agency for Research on Cancer (IARC), an entity of WHO. [18]
Established in 1964, Singapore Cancer Society is a self-funded voluntary welfare organisation which is dedicated to minimize the impact of cancer in Singapore through the provision of cancer treatment subsidies, financial and welfare aid to needy cancer patients, home hospice care services for terminally-ill cancer patients, as well as rehabilitation support programs for recovering cancer ...
6 December – The Singapore Sports Hub has handed over its management to the government sports agency Sports Singapore from its private Sports Hub management to provide an affordable and efficient budgets for more concerts and future National Day Parades (NDPs) to be held there at the National Stadium.
Singapore Health Services, commonly known as SingHealth, is the largest group of healthcare institutions in Singapore. Established in 2000, the group consists of four public hospitals , two community hospitals, five national specialty centres and a network of eight polyclinics .
Overall global cancer incidence (2022) [1] Country Including NMSC Excluding NMSC Number Rate Number Rate Australia 212,332 462.5 151,529 322.4 New Zealand 38,157 427.3
This drug targets a number of cancers, including colorectal, ovarian and pancreatic cancers, which contribute to a significant proportion of Singapore's cancer burden. [16] A*STAR further announced that its second locally developed cancer drug, ETC-206, which targets blood cancers, has advanced to first-in-man trials in 2016. [17]